Trial Profile
A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D [KOS 862] in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Sep 2008
Price :
$35
*
At a glance
- Drugs Epothilone D (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 16 Sep 2008 Actual end date changed from 1 Oct 2002 to 1 Jun 2003 according to ClinicalTrials.gov.
- 16 Sep 2008 Actual end date changed from 1 Oct 2002 to 1 Jun 2003 according to ClinicalTrials.gov.
- 16 Sep 2008 Sponsor and collaborator changed from Kosan Biosciences to Bristol-Myers Squibb according to ClinicalTrials.gov.